Ginzburg named a date for the oncovaccine to be administered to patients
- Новости
- Science and technology
- Ginzburg named a date for the oncovaccine to be administered to patients
Academician of the Russian Academy of Sciences, Director of the Gamaleya National Research Center for Epidemiology and Microbiology, Alexander Gintsburg said that in August the oncovaccine will be approved for use, and in September the first patients will start receiving it. Alexander Gintsburg, director of the Gamaley National Research Center for Epidemiology and Microbiology, said that in August the oncovaccine will be authorized for use, and in September the first patients will start receiving it. He said in a conversation with RIA Novosti on January 27.
"According to that roadmap plan, which we submitted to the Ministry of Health, it has not yet been finally approved, but we should receive authorization at the end of August so that in September we can start treating people," the scientist noted.
According to his information, it is expected that the vaccine will be administered not only to patients with primary melanoma, but also to people who have already been treated.
Earlier, on January 23, Alexander Gintsburg reported that Russian scientists plan to create personalized mRNA vaccines against kidney, breast and pancreatic cancer. In order for the drug to appear, models of cancer diseases will be developed. Vaccine trials are planned for late this year or early 2026, funding permitting.
In October 2024, Gintsburg revealed that the first to receive the personalized Russian oncovaccine will be patients with melanoma (skin cancer). The choice is explained by the fact that this is a superficial disease and in their case it will be easier to observe the effect of the drug. Later, patients with other types of tumors will also receive the vaccine, but there will be no mass testing because the drug is created individually for each person.
Russian President Vladimir Putin said at a meeting with the head of the Federal Medical and Biological Agency (FMBA) Veronika Skvortsova on November 25 that the introduction of a cancer vaccine created in Russia would be a breakthrough. The head of the FMBA told the head of state how the agency's innovative developments in the field of biotechnology, including oncovaccines, were moving forward.
